TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Stock
Certificat
DE000SU0XX58
| Market Closed - Deutsche Boerse AG 15:37:28 2024-05-29 EDT | ||
| 5.27 EUR | +0.76% |
|
| Current month | -4.53% | ||
| 1 month | -8.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 5.27 | +0.76% |
| 24-05-28 | 5.23 | +0.77% |
| 24-05-27 | 5.19 | +2.57% |
| 24-05-24 | 5.06 | 0.00% |
| 24-05-23 | 5.06 | -2.50% |
Delayed Quote Deutsche Boerse AG
Last update May 29, 2024 at 03:37 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU0XX5 |
| ISIN | DE000SU0XX58 |
| Date issued | 2023-10-19 |
| Strike | 1,310 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 8.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.99 € |
|---|---|
| Lowest since issue | 4.91 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
911.5
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.25%
- Stock Market
- Certificates
- Certificat
